Effects of processing of tomato on bioavailability of phenolic compounds and inflammatory biomarkers related to atherosclerosis

Bioavailability of phenolic compounds from tomato depending on its processing. Effects of processing of tomato on cellular and serum biomarkers related to atherosclerosis: An open randomized cross-over controlled trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN20409295

Enrollment

Registered

2010-04-06

Start date

2008-11-03

Completion date

Unknown

Last updated

2019-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bioavailability and Atherosclerosis Circulatory System Atherosclerosis

Interventions

Intervention 1: Administration of 7.14 g/kg of body weight of fresh tomato. Intervention 2: Administration of 3.57 g/kg of body weight of tomato sauce cooked with refined olive oil.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy adults (males and females)

Exclusion criteria

Exclusion criteria: 1. Previous history of cardiovascular disease (ischemic heart disease - angina or recent or old myocardial infarction, cerebral vascular accident, or peripheral vascular disease) 2. Homeostatic disorders 3. Any several chronic diseases 4. Hypertension or dislipemia 5. Smoking subjects 6. Alcoholism 7. Other toxic substance abuse

Design outcomes

Primary

Measure	Time frame
1. Leukocyte adhesion molecule expression: Peripheral lymphocyte and monocyte adhesion molecules on these cells will be marked with monoclonal antibodies (MAb) conjugated with fluorescein-isothiocyanate (FITC) and phycoerythrin (PE) by direct double immunofluorescence. 1.1. MAb used to mark adhesion molecules: 1.1.1. Anti-CD11a (LFA-1) (Bender MedSystems Diagnostics, Vienna) 1.1.2. Anti-CD40L (Bender MedSystems Diagnostics, Vienna) 1.1.3. Anti-CD11b (Mac-1) (Bender MedSystems Diagnostics, Vienna) 1.1.4. Anti-Syalil Lewis (anti-CD15s) (Pharmingen, San Diego, CA) 1.1.5. Anti-CD49d (VLA-4) (Cytogmos) 1.2. MAb used to mark T-lymphocytes: anti-CD2 (Caltag Laboratories, Burlingame, CA) 1.2. MAb used to mark monocytes: anti-CD14 (Caltag Laboratories, Burlingame, CA) 2. Soluble adhesion molecules: The following serum soluble adhesion molecules (1-4) and other molecules (5-7) will be determined by enzyme-linked immunosorbent assay (ELISA) kits (Immunotech): 2.1. Soluble intercellular adhesion molecule-1 (sICAM-1) 2.2. Soluble vascular adhesion molecule 1 (sVCAM-1) 2.3. sE-selectin 2.4. sP-selectin 2.5. Soluble monocyte chemotactic protein-1 (sMCP-1) 2.6. Tumour necrosis factor-alpha (TNF-a) 2.7. Interleukin 1a (IL-1a) 3. Plasma and urine functional components study: 3.1. Plasma polyphenol concentration will be determined by Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS). The plasma polyphenol determinations will be carried out at 8 points during the 24h study, and urine polyphenol determinations at 0-6, 6-12 and 12-24 hours periods with the objective to obtain the plasma and urine phenolics kinetic and to investigate the different kinetic parameters	—

Measure

Time frame

1. Leukocyte adhesion molecule expression: Peripheral lymphocyte and monocyte adhesion molecules on these cells will be marked with monoclonal antibodies (MAb) conjugated with fluorescein-isothiocyanate (FITC) and phycoerythrin (PE) by direct double immunofluorescence. 1.1. MAb used to mark adhesion molecules: 1.1.1. Anti-CD11a (LFA-1) (Bender MedSystems Diagnostics, Vienna) 1.1.2. Anti-CD40L (Bender MedSystems Diagnostics, Vienna) 1.1.3. Anti-CD11b (Mac-1) (Bender MedSystems Diagnostics, Vienna) 1.1.4. Anti-Syalil Lewis (anti-CD15s) (Pharmingen, San Diego, CA) 1.1.5. Anti-CD49d (VLA-4) (Cytogmos) 1.2. MAb used to mark T-lymphocytes: anti-CD2 (Caltag Laboratories, Burlingame, CA) 1.2. MAb used to mark monocytes: anti-CD14 (Caltag Laboratories, Burlingame, CA) 2. Soluble adhesion molecules: The following serum soluble adhesion molecules (1-4) and other molecules (5-7) will be determined by enzyme-linked immunosorbent assay (ELISA) kits (Immunotech): 2.1. Soluble intercellular adhesion molecule-1 (sICAM-1) 2.2. Soluble vascular adhesion molecule 1 (sVCAM-1) 2.3. sE-selectin 2.4. sP-selectin 2.5. Soluble monocyte chemotactic protein-1 (sMCP-1) 2.6. Tumour necrosis factor-alpha (TNF-a) 2.7. Interleukin 1a (IL-1a) 3. Plasma and urine functional components study: 3.1. Plasma polyphenol concentration will be determined by Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS). The plasma polyphenol determinations will be carried out at 8 points during the 24h study, and urine polyphenol determinations at 0-6, 6-12 and 12-24 hours periods with the objective to obtain the plasma and urine phenolics kinetic and to investigate the different kinetic parameters

—

Secondary

Measure	Time frame
1. Medical record: 1.1. A complete medical record will be obtained from all participants, which includes data on tomato intake, smoking and dietary habits. 1.2. Blood pressure and heart rate will be measured with an electronic apparatus Omron HEM-705CP (Netherlands). 2. Nutrition assessment and general analyses: 2.1. All participants will complete a validated nutritional questionnaire at baseline to determine the total quantity of calories ingested in the previous month as well as the proportion corresponding to carbohydrates, lipids and proteins. 2.2. Overall nutrition will be determined by percentage of ideal weight, lean body mass and body mass index. 2.3. Waist perimeter will be measured. 2.4. The following measurements will also be obtained: 2.4.1. Red blood cell count 2.4.2. Haematocrit 2.4.3. Mean corpuscular volume 2.4.4. Leukocyte count 2.4.5. Glucose 2.4.6. Creatinine 2.4.7. Electrolytes 2.4.8. Uric acid 2.4.9. Transaminases 2.4.10. Lactate dehydrogenase 2.4.11. Alkaline phosphatase 2.4.12. Gamma-glutamyl transpeptidase 2.4.13. Bilirubin 3. Coagulation tests: 3.1. Platelet count 3.2. Prothrombin time 3.3. Plasma fibrinogen 4. Serum lipoprotein levels and others 4.1. Total cholesterol 4.2. Triglycerides 4.3. HDL cholesterol (cHDL) 4.4. cLDL 4.5. Apo A1 4.6. Apo B 5. Diet and exercise monitoring: Monitoring of the diet and physical exercise will be carried out before and after each intervention. 5.1. All participants wil	—

Measure

Time frame

1. Medical record: 1.1. A complete medical record will be obtained from all participants, which includes data on tomato intake, smoking and dietary habits. 1.2. Blood pressure and heart rate will be measured with an electronic apparatus Omron HEM-705CP (Netherlands). 2. Nutrition assessment and general analyses: 2.1. All participants will complete a validated nutritional questionnaire at baseline to determine the total quantity of calories ingested in the previous month as well as the proportion corresponding to carbohydrates, lipids and proteins. 2.2. Overall nutrition will be determined by percentage of ideal weight, lean body mass and body mass index. 2.3. Waist perimeter will be measured. 2.4. The following measurements will also be obtained: 2.4.1. Red blood cell count 2.4.2. Haematocrit 2.4.3. Mean corpuscular volume 2.4.4. Leukocyte count 2.4.5. Glucose 2.4.6. Creatinine 2.4.7. Electrolytes 2.4.8. Uric acid 2.4.9. Transaminases 2.4.10. Lactate dehydrogenase 2.4.11. Alkaline phosphatase 2.4.12. Gamma-glutamyl transpeptidase 2.4.13. Bilirubin 3. Coagulation tests: 3.1. Platelet count 3.2. Prothrombin time 3.3. Plasma fibrinogen 4. Serum lipoprotein levels and others 4.1. Total cholesterol 4.2. Triglycerides 4.3. HDL cholesterol (cHDL) 4.4. cLDL 4.5. Apo A1 4.6. Apo B 5. Diet and exercise monitoring: Monitoring of the diet and physical exercise will be carried out before and after each intervention. 5.1. All participants wil

—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026